~~<i id='2ED22DDE49'><strike id='2ED22DDE49'><tt id='2ED22DDE49'><pre id='2ED22DDE49'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：comprehensive 2025-10-06 08:13:26 - browse：44

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The Readout: Lenmeldy, GLP

explore

focus

Wikipedia

focus

LaneTurner/GlobeStaffContemporarypaintingsbyartistswhohaveovercomehomelessnessordisabilitiesgreetvis

WSS

The Readout: Lenmeldy, GLP

Gene therapy denied for Afghan refugee whose father aided U.S.

Boston Scientific acquires urology company Axonics for $3.7 billion

Supreme Court mifepristone arguments center on docs' right to sue

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

focus

entertainment

explore

Medical leaders decry Supreme Court decision on affirmative action

Merck drug for rare lung condition set for approval in U.S.

The high cost of giving birth even with insurance

A preacher's new calling: Diversifying neuroscience research

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Readout: Lenmeldy, GLP

Psychedelics group wrestles with new pharma identity

Abortion pill case raises question: who can sue the FDA?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

States should stop sabotaging methadone treatment reform

focus

Medicare Advantage overpayments discussion gets experts fired up

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Patient advocates debate FDA's accelerated approval process

Eliminate the waiting period for sterilization covered by Medicaid

Covid vaccine financial winners and losers, from Pfizer to Novavax

At JPM 2024, hospital systems pitch financial strength to investors

focus

focus

Wikipedia

focus